ChemoMetec ASOCSE:CHEMM +0.15%99 EV-to-FCF is 51.38 as of Jul. 04, 2026, which is 40% below its 10-year median of 86.17. GuruFocus rates OCSE:CHEMM with a GF Score™ of 99/100 and a GF Value™ of kr549.48 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 418 Medical Devices & Instruments companies, ChemoMetec AS ranks worse than 73.92% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, ChemoMetec AS's Enterprise Value is kr6,820.3 Mil.
ChemoMetec AS's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was kr132.7 Mil. Therefore, ChemoMetec AS's EV-to-FCF for today is 51.38.
The historical rank and industry rank for ChemoMetec AS's EV-to-FCF or its related term are showing as below:
OCSE:CHEMM'
s EV-to-FCF Range Over the Past 10 Years
Min: -1196.48 Med: 86.17 Max: 306.54
Current: 46.55
During the past 13 years, the highest EV-to-FCF of ChemoMetec AS was 306.54. The lowest was -1196.48. And the median was 86.17.
OCSE:CHEMM's EV-to-FCF is ranked worse than 73.92% of 418
companies
in the Medical Devices & Instruments industry
Industry Median: 23.12
vs OCSE:CHEMM: 46.55
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
ChemoMetec AS's PE Ratio (TTM) for today is calculated as:
ChemoMetec AS's share price for today is kr407.40.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. ChemoMetec AS's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was kr10.170.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
ChemoMetec AS EV-to-FCF Related Terms
ChemoMetec AS EV-to-FCF Historical Data
* Premium members only.
The historical data trend for ChemoMetec AS's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, ChemoMetec AS's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ChemoMetec AS EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, ChemoMetec AS's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where ChemoMetec AS's EV-to-FCF falls into.
ChemoMetec AS's current Enterprise Value is kr6,820.3 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. ChemoMetec AS's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was kr132.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ChemoMetec AS (OCSE:CHEMM) has a EV-to-FCF of 51.38 as of Jul. 04, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on ChemoMetec AS and its competitors. This is 40% below median its historical median of 86.17. According to the industry distribution chart, ChemoMetec AS ranks #309 out of 418 companies in the Medical Devices & Instruments industry, placing it in the top 73.9%.
Is ChemoMetec AS's EV-to-FCF too high?
ChemoMetec AS's current EV-to-FCF of 51.38 is 40% below median its 10-year median of 86.17. The Medical Devices & Instruments industry median EV-to-FCF is 23.12. ChemoMetec AS's value of 51.38 is 122.2% above this industry median. Based on the distribution chart, ChemoMetec AS ranks #309 out of 418 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, ChemoMetec AS has a GF Score™ of 99/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ChemoMetec AS's EV-to-FCF compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, ChemoMetec AS ranks #309 out of 418 companies for EV-to-FCF. This places ChemoMetec AS in the lower half of its industry. The industry median EV-to-FCF is 23.12. ChemoMetec AS's value of 51.38 is 122.2% above this benchmark. While the company's 10-year median is 86.17 vs. the industry median of 23.12, ChemoMetec AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 23.12, based on 418 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ChemoMetec AS's current EV-to-FCF of 51.38 is 122.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on ChemoMetec AS and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 23.12 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ChemoMetec AS's current EV-to-FCF is 51.38, which is 40% below median its own 10-year median of 86.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ChemoMetec AS stock overvalued right now?
Based on GuruFocus' analysis, ChemoMetec AS (OCSE:CHEMM) is currently considered Modestly Undervalued. The stock's GF Value™ is kr549.48, compared to a current price of kr407.40 — trading 25.9% below its estimated fair value. The current EV-to-FCF is 51.38, which is 40% below median its 10-year median of 86.17 and 122.2% above the Medical Devices & Instruments industry median of 23.12. ChemoMetec AS's overall GF Score™ is 99/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For ChemoMetec AS (OCSE:CHEMM), the current EV-to-FCF is 51.38 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ChemoMetec AS (OCSE:CHEMM) Overvalued in 2026?
Based on GuruFocus' analysis, ChemoMetec AS stock appears to be undervalued.
The current stock price of kr407.40 is trading 25.9% below its estimated GF Value™ of kr549.48.
GuruFocus considers ChemoMetec AS to be Modestly Undervalued.
Key valuation signals for OCSE:CHEMM:
EV-to-FCF: 51.38 (40% below median its 10-year median of 86.17)
GF Value™: kr549.48 vs. price of kr407.40 (25.9% below fair value)
Industry Position: 122.2% above the Medical Devices & Instruments median (#309 of 418)
No single metric tells the full story. See the OCSE:CHEMM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ChemoMetec AS specializes in designing, developing, and producing instruments using patented technology in cell counting and evaluation. It is engaged in the manufacturing and marketing of analytical instruments used for quantitative analysis of cells in liquids. Its applications include Cell Analysis and counting of Mammalian Cells, Yeast Cells, and Sperm Cells. It provides platforms for the determination of viability and cell count of yeast, veterinary semen, mammalian cells, and somatic cells as well as image analysis. It has four segments instruments; consumables; services and others, and the majority of its revenue is generated from the Consumable segment.
99GF Score
Get the complete analysis for OCSE:CHEMM
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OCSE:CHEMM has been successfully added to your 
